Is Korean society prepared for the financial burden of novel anticancer drugs? A survey of willingness to pay among National Health Insurance beneficiaries.

Han, Kyu-Tae; Yu, Ye Lee; Kim, Woorim; Kang, Sokbom

Han, Kyu-Tae; Yu, Ye Lee; Kim, Woorim; Kang, Sokbom.

Afiliação

Han KT; Division of Cancer Control and Policy, National Cancer Control Institute, National Cancer Center Korea, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea.
Yu YL; Division of Precision Medicine, Research Institute, National Cancer Center Korea, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea.
Kim W; Division of Cancer Control and Policy, National Cancer Control Institute, National Cancer Center Korea, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea.
Kang S; Division of Precision Medicine, Research Institute, National Cancer Center Korea, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea. sokbom@ncc.re.kr.

Support Care Cancer ; 29(11): 6681-6688, 2021 Nov.

Article em En | MEDLINE | ID: mdl-33963909

Assuntos

Antineoplásicos; Gastos em Saúde; Humanos; Seguro Saúde; Programas Nacionais de Saúde; República da Coreia; Inquéritos e Questionários

Palavras-chave

Anticancer drug; Insurance premium; Threshold effect; Willingness to pay

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Gastos em Saúde / Antineoplásicos Tipo de estudo: Etiology_studies / Health_economic_evaluation Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google